Shein wins CSRC approval for Hong Kong IPO

Shares of e-paper display maker DKE Holding Co. Ltd. (1770.HK) opened 1.89% lower in their Hong Kong trading debut on Thursday, before rebounding to HK$78.8 by the midday break, up 0.2%.

The company said it issued 5.12 million shares at an offer price of HK$78.64 per share, raising net proceeds of about HK$355.4 million ($45 million). Its Hong Kong public offering for local investors was oversubscribed by more than 1,000 times, while the international placement was oversubscribed by 2.69 times.

DKE develops, produces and sells e-paper display modules. E-paper is a low-power display technology that mimics the appearance of paper. It consumes almost no power when an image remains static, and is commonly used in e-readers, electronic shelf labels, smart offices, smart logistics and transport information displays.

The company said that by 2025 revenue, it was the world’s second-largest e-paper display manufacturer with a market share of 20.8%, and the world’s largest commercial e-paper display manufacturer with 24.9% of the market. Its revenue last year rose 48.8% to 1.71 billion yuan ($252 million), while its net profit increased about 50.2% to 80.23 million yuan.

The company said about 65% of the proceeds will be used to expand capacity and digitalize its production bases, 25% will be used to develop full-color, large-sized and flexible e-paper products and the remaining 10% will be used for working capital and general corporate purposes.

The company was originally scheduled to list on July 8, but postponed its debut to July 9 to finalize its pricing and allotment announcement and obtain regulatory approval.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Salubris refiles for Hong Kong IPO

Salubris refiles for Hong Kong IPO as generics lose steam

The producer of cardiovascular drugs is accelerating its shift towards innovative pharmaceuticals, under pressure from price cuts and expiring patents Key Takeaways: Salubris built its early success on generics, but…